Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0038389992
Fri, 21.10.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
October 21, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss [ … ]
Fri, 21.10.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
October 21, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss [ … ]
Fri, 22.07.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the [ … ]
Fri, 22.07.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the [ … ]
Fri, 22.04.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
April 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022.
Based on the consolidated accounts of BB Biot [ … ]
Fri, 18.02.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
February 18, 2022
Annual report of BB Biotech AG as at December 31, 2021
BB Biotech AG publishes its 2021 annual report
BB Biotech AG published its annual report for fiscal year 2021 today. Besides the audited consolidated financial statements, the annual report contains detailed i [ … ]
Fri, 21.01.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
January 21, 2022
BB Biotech AG closes the 2021 fiscal year with a loss
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2021.
Based on its preliminary unaudited cons [ … ]
Fri, 22.10.2021
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
October 22, 2021
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2021, which covers the results of its business activities for the first nine months of 2021.
Based on the consolidated accounts of B [ … ]
Fri, 23.07.2021
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
July 23, 2021
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2021, which covers the results of its business activities for the first six months of 2021.
Based on the consolidated accounts of BB Biotech [ … ]
Fri, 23.04.2021
BB BIOTECH AG
Media Release, April 23, 2021
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2021, which covers the results of its business activities for the first three months of 2021.
Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2 [ … ]